Heparin Resistance — Clinical Perspectives and Management Strategies

Heparin Resistance — Clinical Perspectives and Management Strategies

Heparin resistance is suspected when more heparin than usual is needed to achieve a therapeutic range of activated partial-thromboplastin time. Management may include increasing the heparin dose, supplementing antithrombin III levels, and using direct thrombin inhibitors.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-08, Vol.385 (9), p.826-832, Article 826
Hauptverfasser: Levy, Jerrold H, Connors, Jean M
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Anticoagulation
Antithrombin
Cardiology
Coagulation
Congenital diseases
Coronaviruses
COVID-19
Critical Care
Drug dosages
Drug resistance
Extracorporeal membrane oxygenation
Glycoproteins
Hematology
Heparin
Laboratories
Oncology
Patients
Plasma
Polymers
Proteins
Pulmonary
Thrombin
Thromboembolism
Thromboplastin
Thrombosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Heparin resistance is suspected when more heparin than usual is needed to achieve a therapeutic range of activated partial-thromboplastin time. Management may include increasing the heparin dose, supplementing antithrombin III levels, and using direct thrombin inhibitors.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMra2104091